Tanabe Mitsubishi Applies For DPP-4 Inhibitor Tenelia Combination Therapy
This article was originally published in PharmAsia News
Executive Summary
Tanabe Mitsubishi has applied for an additional indication for DPP-4 inhibitor 20mg Tenelia tablets (teneligliptin hydrobromide hydrate) for use in combination therapy, the company announced on Feb. 26.